期刊
JOURNAL OF CLINICAL PHARMACOLOGY
卷 51, 期 1, 页码 75-83出版社
WILEY
DOI: 10.1177/0091270010367428
关键词
Nilotinib; pharmacokinetics; CYP3A4 inhibition; CYP3A4 induction
资金
- Novartis Pharmaceuticals Corporation
- Novartis Pharmaceuticals
Nilotinib (Tasigna), an orally bioavailable second-generation BCR-ABL tyrosine kinase inhibitor, is approved for use in patients with chronic myeloid leukemia in chronic phase and accelerated phase who are resistant or intolerant to prior therapy, including imatinib. Previous in vitro studies indicated that nilotinib metabolism is primarily mediated by CYP3A4. To investigate the effect of CYP3A4 induction and inhibition on nilotinib pharmacokinetics, 2 studies were conducted in healthy volunteers prior to and following treatment with a strong inducer (rifampin) or inhibitor (ketoconazole). In the induction study, administration of rifampin 600 mg once daily for 8 days significantly increased urinary 6 beta-hydroxycortisol/cortisol ratio, from a preinduction baseline of 5.8 +/- 2.7 to 18.0 +/- 10.2 after 8 days of rifampin treatment, confirming an inductive effect on CYP3A4. Nilotinib oral clearance was increased by 4.8-fold, and the maximum serum concentration (C-max) and area under the serum concentration- time curve (AUC) were decreased by 64% and 80%, respectively, in the induced state compared with baseline. In the inhibition study, ketoconazole 400 mg once daily for 6 days increased the C-max and AUC of nilotinib by 1.8-and 3-fold, respectively, compared with nilotinib alone. These results indicate that concurrent use of strong CYP3A4 inducers or inhibitors may necessitate dosage adjustments of nilotinib and should be avoided when possible.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据